TRANSLATE-TIMI 70 is a phase 2b trial testing multiple doses of vupanorsen, an antisense oligonucleotide (ASO) against angiopoietin-like 3 (ANGPTL3) mRNA, for safety and efficacy in non-HDL-C lowering.
MAIN RESULTS:
Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70
Circulation. 2022 May 3;145(18):1377-1386.
PRESENTATIONS
TRANSLATE Main Results (Bergmark ACC 2022)
Hepatic Fat Changes After An Antisense Oligonucleotide Therapy Targeting ANGPTL3: A TRANSLATE-TIMI 70 Analysis (Zimerman, ACC 2023)
TRANSLATE on ClinicalTrials.gov